Year: 2005
Type: conference-abstract
Abstract: Background: Sorafenib (BAY 43-9006), an oral inhibitor of multiple kinases including Raf, VEGFR, p38, c-Kit, flt3, exerts a dual mode of action by inhibiting tumor cell proliferation and angiogenesis.A prior Phase II randomized discontinuation trial demonstrated activity of sorafenib in patients (pts) with metastatic RCC.The primary aim of this Phase III, double-blind trial was to assess overall survival (OS) in pts with confirmed advanced clear-cell RCC randomized to BAY vs. best supportive care (BSC).Results of a planned analysis on the secondary endpoint, progression-free survival (PFS), are presented in this report.Methods: Pts (ECOG 0-1) who had received one prior systemic therapy for advanced RCC were stratified into low or intermediate risk factor groups, according to the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic index.Pts were randomized to receive continuous oral sorafenib 400 mg bid or placebo with BSC.A single PFS analysis was planned using a 2-sided alpha level of 0.01 by log-rank test stratified by prognostic group and country.Adverse events (AE) were tabulated by CTCAE v3.0.Results: At the time of the PFS analysis, 769 of the planned 884 pts were randomized and 342 PFS events were reported.Demographic and baseline prognostic characteristics were similar between BAY and placebo [pooled results: mean age 59 yrs; ECOG 0:1 (47%:51%); MSKCC prognostic index low:intermediate (51%:49%); prior cytokine therapy 82%; prior nephrectomy 93%].Median PFS as assessed by independent review was 24 weeks for BAY vs. 12 weeks for placebo (hazard ratio BAY/placebo 0.44; p-value Ͻ 0.00001).The 12-week progression-free rate was 79% for BAY vs. 50% for placebo.Drugrelated AE (all grades) for BAY vs. placebo included rash (34%:13%), diarrhea (33%:10%), hand-foot skin reaction (27%:5%), fatigue (26%:23%) and hypertension (11%:1%).Any grade 3/4 events were reported in 30% pts on BAY vs. 22% pts on placebo.Study follow-up is ongoing to complete the OS endpoint.Conclusions: BAY significantly prolongs progression-free survival compared with placebo in pts with previously treated advanced RCC, with a favorable safety profile.
Source: Oncology Research and Treatment
DOI: 10.1159/000088351
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: sorafenib, clear cell renal cell carcinoma, metastatic renal cell carcinoma, progression-free survival, best supportive care, tyrosine kinase inhibitors, adverse events, hand-foot skin reaction, hypertension, diarrhea, rash, fatigue, overall survival, independent review committee, ECOG performance status
Open Access status: hybrid
OpenAlex ID: W4251349254
